ReviewTherapeutic advances in gastroenterology2019
Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities.
Review in Therapeutic advances in gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A bibliometric study on the impact of gut microbiota on the efficacy of immune checkpoint inhibitors in cancer patients: analysis of the top 100 cited articles.Frontiers in immunology · 2024Pooled it
- Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review.Digestive diseases and sciences · 2022Pooled it
- Pneumatosis intestinalis revisited: associated imaging findings, clinical correlation, management, risk stratification and future perspectives.Emergency radiology · 2026Review
- The Relationship Between (Endo)cannabinoids, the Microbiome and Melanoma.Pharmacology research & perspectives · 2026Review
- Intratumoral microbiome: the double-edged sword in remodeling cancer immunotherapy.Molecular cancer · 2026Review
- Integrated metabolomics and machine learning identify predictive biomarkers via SHAP analysis for sintilimab-induced rash in lung cancer patients.Frontiers in pharmacology · 2026Article
- Exploring the etiology of colitis: insights from gut microbiota research.Gut microbes · 2025Review
- Individualized metagenomic network model for colorectal cancer diagnosis: insights into viral regulation of gut microecology.Briefings in bioinformatics · 2025Article
- Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome.Journal of clinical medicine · 2025Review
- Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management.Immunotherapy · 2025Review
- Article
- Gut microbiome for predicting immune checkpoint blockade-associated adverse events.Genome medicine · 2024Article
- Can physiologic colonic [European journal of nuclear medicine and molecular imaging · 2023Article
- Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.European journal of cancer (Oxford, England : 1990) · 2023Article
- Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota.International journal of molecular sciences · 2023Review
- Review
- The Modulatory Effects of Fatty Acids on Cancer Progression.Biomedicines · 2023Review
- Gastrointestinal injury induced by immunomodulators: A review article.Therapeutic advances in gastroenterology · 2023Review
- Cancer Microbiology.Journal of the National Cancer Institute · 2022Article
- Machine learning from Pseudomonas aeruginosa transcriptomes identifies independently modulated sets of genes associated with known transcriptional regulators.Nucleic acids research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have transformed the treatment of patients with advanced cancers. However, the majority of patients do not respond or develop early progressive disease. A substantial number also develop immune-mediated toxicities that may lead to early treatment discontinuation. Gastrointestinal toxicities in the form of diarrhea and colitis are common and may resemble that observed in patients with inflammatory bowel disease (IBD). Alterations in the gut microbiota are thought to play an important role in mediating the intestinal inflammation that is associated with immune-mediated colitis. In this review, the authors' objective is to provide an overview of the gastrointestinal and hepatic toxicities that can be seen with ICIs and discuss the interactions between gut microbiota and the immune response. The authors also highlight the potential role for fecal microbial transfer (FMT) as an approach to improve therapeutic efficacy and decrease toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.